Pharmacokinetic aspects of protriptyline plasma levels

Area of Science:

• Pharmacology
• Clinical Pharmacy

Background:

• Antidepressant therapy requires careful management of drug plasma levels for efficacy.
• Protriptyline is a tricyclic antidepressant with variable pharmacokinetic profiles.

Purpose of the Study:

• To determine protriptyline plasma levels in patients undergoing antidepressant therapy.
• To investigate the influence of sedatives on protriptyline plasma concentrations.
• To assess the predictability of early plasma levels for long-term therapeutic outcomes.

Main Methods:

• Plasma protriptyline levels were measured in 30 patients after 3.5 weeks of treatment at 40 mg/day.
• Single-dose pharmacokinetic studies were conducted in 5 volunteers.
• The impact of nitrazepam and sodium amylobarbitone on protriptyline levels was evaluated.

Main Results:

• Protriptyline plasma levels ranged from 430 to 1430 nmol/l, with two-thirds achieving asymptotic concentrations.
• Volume of distribution showed minimal intersubject variation, but half-life varied from 54 to 198 hours.
• Nitrazepam did not affect protriptyline levels, while sodium amylobarbitone significantly reduced them.

Conclusions:

• Protriptyline pharmacokinetics exhibit significant intersubject variability, particularly in half-life.
• Concurrent use of sodium amylobarbitone may decrease protriptyline efficacy.
• Early plasma protriptyline level monitoring can guide timely dosage adjustments for optimal therapeutic outcomes.